A share price of Ovid Therapeutics Inc [OVID] is currently trading at $1.32, up 1.54%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OVID shares have lost -2.22% over the last week, with a monthly amount drifted -20.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on October 09, 2025, and set its price target to $7. Oppenheimer downgraded its rating to a Perform. B. Riley Securities initiated its recommendation with a Buy and recommended $9 as its price target on April 30, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on April 29, 2024, and assigned it a price target of $9. In a note dated April 05, 2024, Wedbush initiated an Outperform rating and provided a target price of $8 on this stock.
Ovid Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.24 and $2.01. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $1.32 at the most recent close of the market. An investor can expect a potential return of 455.3% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Trailing Twelve Months sales for Ovid Therapeutics Inc [NASDAQ:OVID] were 6.61M which represents -23.70% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -6.18%, Pretax Profit Margin comes in at -5.5%, and Net Profit Margin reading is -5.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.64 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2633 points at the first support level, and at 1.2067 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3533, and for the 2nd resistance point, it is at 1.3867.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ovid Therapeutics Inc [NASDAQ:OVID] is 4.24. Further, the Quick Ratio stands at 4.24, while the Cash Ratio is 3.03. Considering the valuation of this stock, the price to sales ratio is 14.22, the price to book ratio is 2.10.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
